Respiratory Syncytial Virus Infections among Children with Congenital Heart Disease by Daurach, Maja & Michel-Behnke, Ina
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Respiratory Syncytial Virus 
Infections among Children with 
Congenital Heart Disease
Maja Daurach and Ina Michel-Behnke
Abstract
Infants and children suffering from congenital heart disease represent a 
patient cohort particularly at risk for severe RSV infections. Most notably the 
complication rates in lower respiratory tract infections due to RSV among patients 
with congenital heart disease are significantly higher compared to other patient 
collectives. Predisposing factors are altered lung mechanics caused by either 
increased or decreased pulmonary blood flow, both resulting in a ventilation/
perfusion mismatch causing decreased pulmonary compliance and higher airway 
resistance. Randomized controlled trials have shown that immunoprophylaxis 
with palivizumab is beneficial for CHD patients. Guidelines from different 
national societies suggest administration of palivizumab for infants with CHD in 
young age injected monthly throughout the RSV season, if the CHD is considered 
hemodynamically significant.
Keywords: congenital heart disease (CHD), respiratory syncytial virus (RSV), 
palivizumab, immunoprophylaxis, lower respiratory tract infection (LRTI), 
bronchiolitis
1. Introduction
The burden of respiratory syncytial virus (RSV) infections differs markedly 
between patients. Clinical symptoms might be mild as in a common cold, while at 
the other end of the spectrum, children suffer from serious complications  
and negative impact with chronic respiratory problems that can persist into 
adulthood [1].
Since the 1980s infants and young children with congenital heart defects 
(CHD) have been shown to be a particularly vulnerable population developing 
severe lower respiratory tract infections (LRTIs) caused by RSV. The severity of 
infections in children with CHD was significantly higher than severity in children 
without CHD [2].
This chapter will provide an overview of the current state of knowledge regard-
ing RSV infections in children with CHD. In particular, we try to elucidate the 
mechanisms for the susceptibility of children with congenital heart defects to 
experience critical illness from RSV LRTI.
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2. Mechanisms of susceptibility caused by congenital heart disease
In general pulmonary compliance and airway resistance determine the breath-
ing. The airways of young infants have greater airway resistance due to their smaller 
diameter. Spontaneous breathing of infants is characterized by a functional residual 
capacity that is less than the closing capacity, which leads to areas of mechanical 
collapse of the alveoli. As a result the infant itself is more susceptible to develop 
ventilation/perfusion mismatch and is at higher risk for respiratory problems just 
from anatomy and pathophysiology irrespective of congenital heart disease [3].
As cardiac and pulmonary function is closely related, the baseline risk of the 
young infant is increased by several predisposing factors due to CHD.
Pulmonary sequelae and complications of CHD can be anatomical due to 
compression of the lung by, e.g., cardiomegaly, subsequently causing atelectases 
or airway malacia. Surgical or anesthesiologic trauma can result in chylothorax, 
subglottic stenosis, and laryngeal or phrenic nerve palsy leading to respiratory 
distress [4].
On the other hand, in particular the altered hemodynamics in CHD contributes 
to an increased vulnerability of the lung. In this context cardiac defects can be 
categorized in three main categories: (1) those with left-to-right shunt lesions, (2) 
those with right-to-left shunt lesions, and (3) those with more complex mixing 
patterns [5].
2.1 Left-to-right shunt lesions: pulmonary overflow
Typically CHDs with left-to-right shunt are acyanotic. They include atrial septal 
defects (ASDs), ventricular septal defects (VSDs), patent ductus arteriosus (PDA), 
atrioventricular septal defects (AVSDs), or double outlet right ventricles (DORV) 
with normally related great vessels (i.e., with VSD physiology). Very rarely coronary 
fistula or other extracardiac shunts are detected to cause volume overload of the 
right heart and the lungs.
When there is unrestricted communication between systemic and pulmonary 
circulation, the shunt volume is depending on the relative resistance in the two cir-
cuits with physiologically lower pulmonary resistance. During the normal transition 
of an infants’ blood circulation in the first months of life, the decrease of pulmo-
nary arteriolar resistance leads to an increase of left-to-right shunt. As a result the 
pulmonary blood flow is increasing (see Figure 1). Subsequently the lung volume 
and pulmonary artery pressure are elevated, and finally the capillary and left atrial 
pressures increase. At the end lung edema develops with high lung resistance. 
Alveolar edema and thus higher lung weight result in reduced lung compliance and 
therefore a decreased ventilation/perfusion ratio leading to intrapulmonary mis-
match and eventually hypoxemia.
2.2 Right-to-left shunt lesions: diminished pulmonary flow
Intracardiac right-to-left shunt leads to cyanosis. The basic pathophysiology of 
the most frequent cyanotic CHD is the tetralogy of Fallot (TOF) and includes an 
unrestricted communication between systemic and pulmonary circulation (VSD) 
and obstruction of the pulmonary outlet (see Figure 2). In these patients the main 
hemodynamic difference is reduced pulmonary blood flow, therefore lower lung 
volume and hypoplastic airways. The hypoplastic airways are more susceptible 
to obstruction and lead to higher airway resistance. Ventilation/perfusion ratio 
is increased in these patients causing dead space ventilation, which aggravates an 
already preexisting hypoxemia.
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2.3 Complex CHD with mixed physiology
In patients with complex CHD, cyanosis and relatively increased pulmonary 
blood flow may occur at the same time. Examples are hypoplastic left heart 
Figure 1. 
VSD. Pulmonary overflow due to left-to-right shunt through a ventricular septal defect (VSD).
Figure 2. 
TOF. Cyanosis due to right-to-left shunt through a VSD when pulmonary stenosis and hypoplastic pulmonary 
arteries are present in tetralogy of Fallot (TOF).
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syndrome (Figure 3) or other forms of functionally single ventricle like hypoplastic 
right heart, tricuspid atresia, or pulmonary atresia. Insertion of systemic to pulmo-
nary shunt as part of the first stage of palliative surgery ideally leads to a balanced 
pulmonary and systemic perfusion but for the sake of an increased volume load and 
persisting cyanosis.
These patients are at high risk for ventilation-perfusion mismatch. In addition, 
impaired ventricular function may contribute to higher pulmonary venous pres-
sures leading to pulmonary venous congestion and subsequently lung edema and 
higher pulmonary artery pressures [3, 5].
Pulmonary hypertension is known to exacerbate these effects and represents a 
particular predisposing factor for fatal disease [6].
In the end many complex risk factors are responsible for the susceptibility of 
young CHD patients. Compromised cardiorespiratory status at baseline, altered 
pulmonary mechanics, potential cyanosis and/or pulmonary hypertension, and 
ventilation-perfusion mismatch can increase the negative effects of respiratory dis-
ease in this vulnerable patient cohort unable to compensate properly for intercur-
rent disease. The interplay of the distinct circulation in CHD and the consequences 
on lung architecture and function contribute to the elevated risk to which these 
patients are exposed by an RSV infection [5, 7].
3. RSV-related morbidity of children with CHD
RSV accounts for about 20% of all respiratory infections in children below 
the age of 5 years. Most infections occur in the first 2 years of life. In healthy term 
infants, hospitalization rates due to RSV LRTI range from 1 to 3%, mainly in the 
first 6 months of life. Among high-risk populations like preterm infants with or 
without bronchopulmonary dysplasia (BPD), infants with CHD, Down syndrome, 
neuromuscular disease, immunosuppressed children, or patients with severe 
immune deficiency syndromes, hospitalization rates increase up to 10% [8].
Figure 3. 
Norwood-I palliated HLHS. Excessive pulmonary perfusion via Sano shunt leads to relative overflow of  
the pulmonary arteries, dilated left atrium resulting in higher pulmonary vein pressure causing pulmonary 
vein congestion.
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As shown in a systematic review as part of the RSV Evidence—A Geographical 
Archive of Literature (REGAL) series published in 2017 including 38 studies 
reporting RSV-associated morbidity and mortality, the risk and burden of RSV in 
CHD still remain serious. RSV hospitalization rates were generally high in young 
children (<4 years) with CHD varying between 14 and 357/1000 patients. Infants 
(<2 years) with CHD had a more severe course of RSV infections than patients 
without CHD. Duration of hospital stay was 4.4–14 days, up to 53% of them requir-
ing intensive care. Case fatality rates of up to 3% were associated with RSV LRTIs in 
children with CHD. RSV infection in the perioperative period of cardiac surgery and 
nosocomial infections in ICUs also represent an important cause of morbidity [9].
A recent investigation in Austria analyzed data on RSV-related hospitalizations 
in infants and small children in their first three RSV seasons (November–April). 
The study was performed retrospectively and included children with CHD born 
between 2004 and 2008. The study cohort included 602 patients of whom 451 
(74.9%) had hemodynamically not significant CHD (HNS-CHD), 102 (16.9%) 
had acyanotic, and 49 (8.1%) had cyanotic hemodynamically significant CHD 
(HS-CHD). Pulmonary hypertension was present in 48 of 151 (31.8%) patients 
with hemodynamically significant CHD. Overall incidence of RSV-related hospi-
talizations was 9.6%. Hospitalization rates between hemodynamically significant 
(10.4%) and not significant CHD (7.3%) did not differ significantly. The median 
duration of hospitalization was 8.5 days, whereas in HS-CHD the length was 14 days 
compared to 7 days in HNS-CHD. These results demonstrate the more severe course 
of RSV infections in children with hemodynamically significant disease. The 
median duration of supplemental oxygen was 1 day (0–38 days). 22.4% of children 
were treated at the ICU; the median duration of ICU stay was 10 days (2–70 days), 
and the median duration of mechanical ventilation was 4 days (0–38 days). 
Children with hemodynamically significant disease and early heart surgery were 
less often hospitalized compared to those with delayed cardiac surgery [10].
In order to investigate case fatality rates in young children hospitalized because 
of RSV LRTIs, a systematic review of 34 articles was conducted in 2012. The case 
fatality rates for RSV-associated bronchiolitis and pneumonia among patient col-
lectives of children, who are at particular high risk, were compared. The subgroups 
included (1) preterm infants, born before 37 gestational weeks, (2) children with 
diagnosed bronchopulmonary dysplasia (BPD) within the first 2 years of life, and 
(3) children with diagnosed CHD within the first 2 years of life. Case fatality rate 
among preterm infants was 1.2% (0–8.3%, median 0%), among children with BPD 
4.1% (0–10.5%, median 7.0%) and among children with CHD 5.2% (2.0–37%, 
median 5.9%). While case fatality estimates among children not at high risk ranged 
from 0 to 1.5% (weighted mean 0.2%, median 0.0%), case fatality rates among 
children at elevated risk of RSV LRTI were significantly higher with the highest case 
fatality rate for children with diagnosed CHD [11].
All these papers underline the fact that infants and children with CHD especially 
when hemodynamically significant represent an extremely sensitive patient collec-
tive when it comes to RSV disease. Most strikingly they tend to have a more severe 
course and worse outcome of LRTIs due to RSV.
4. Prevention of RSV
RSV is the most common cause of LRTIs in infants and toddlers and under 
certain circumstances like in HS-CHD puts the children at elevated risk to develop 
respiratory or cardiac failure. Therefore, specific infection control measures are 
necessary to prevent severe RSV infections [12].
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Comprehensive hygiene measures are efficacious and cost-effective in preventing 
the spread of RSV and should always be advocated as a main prophylactic factor. Breast 
feeding and avoidance of exposure to tobacco and other smoke are further important 
facts in the prevention of RSV disease [13, 14]. Delayed day-care attendance in high-
risk populations may represent a preventive factor from acquiring RSV infections [15].
As mentioned above early surgical correction of CHD remains a prophylactic 
factor for severe RSV LRTI [10].
Although vaccine candidates have been in clinical evaluation for nearly 50 years, 
none, to date, have reached licensing. Palivizumab, a humanized monoclonal 
antibody, is currently the only intervention licensed for the prevention of severe 
RSV disease [8].
4.1 Palivizumab prophylaxis
In June 1998, palivizumab was licensed by the US Food and Drug Administration 
(FDA) for prevention of serious LRTI caused by RSV in pediatric patients, who are 
at increased risk of severe disease including young children suffering from CHD 
[16]. The efficacy and safety of palivizumab have been evaluated in many multi-
center randomized controlled trials as shown in the following data [17–19].
In 2003 a prospective, randomized, double-blind, placebo-controlled mul-
ticenter trial including 1287 children with CHD was published. The study was 
conducted in the RSV seasons 199–2002 (seventy-six centers in the USA, six in 
Canada, three in Sweden, four in Germany, six in Poland, four in France, and six in 
the UK). The primary objective was to compare the safety, tolerance, and efficacy of 
palivizumab with placebo. The secondary objectives were to determine the effect of 
monthly administered palivizumab on hospitalization outcomes (total hospitaliza-
tion duration, days with increased oxygen requirement, incidence, and total days 
of ICU stays and RSV-associated mechanical ventilation), as well as to describe 
the effect of cardiac bypass on serum palivizumab levels and determine the palivi-
zumab levels before the second and fifth doses.
Children aged less than 24 months, who had documented hemodynamically sig-
nificant CHD, not yet corrected or partially corrected, were included. Patients were 
randomly assigned 1:1 to receive either 5 monthly (every 30 days) intramuscular 
injections of 15 mg/kg body weight palivizumab or placebo. Children were followed 
for 150 days for hospitalization and occurrence of adverse events. Monthly prophy-
laxis with palivizumab was associated with a 45% relative reduction in RSV hos-
pitalization rate (9.7% in the placebo group, 5.3% in the palivizumab group). The 
length of total hospital stays was reduced by 56% (129 days in the placebo group vs. 
57.4 days in the palivizumab group), days with increased oxygen requirement were 
reduced by 73% (101.5 days placebo vs. 27.9 days palivizumab), days at ICU were 
reduced by 78%, and days on mechanical ventilation showed a 41% reduction.
Regarding safety and tolerability, the incidence of adverse events in the palivi-
zumab and placebo group was similar. None of the children had drug-related severe 
adverse events.
The effect of cardiopulmonary bypass on serum palivizumab levels showed a 
notable decrease (58%) of antibody titers making early restart of palivizumab injec-
tions necessary [17].
Another paper documenting the effects of palivizumab in subjects with CHD 
was published in 2008. During the RSV seasons 2000–2004, data from 19,548 sub-
jects who received immunoprophylaxis with palivizumab were collected prospec-
tively in the palivizumab outcomes registry. One thousand five hundred subjects 
with CHD (7.7% of the entire cohort) were enrolled. Seventy-one percent had 
acyanotic CHD. About 1.9% of patients prophylactically treated with palivizumab 
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were hospitalized because of RSV infections, compared to 1.2% of patients included 
in the registry without CHD, which are low hospitalization rates compared to 
hospitalization rates before immunoprophylaxis [18].
A further study evaluated the impact of palivizumab prophylaxis on RSV hospi-
talizations among children with hemodynamically significant CHD by comparing 
the outcome before and after palivizumab prophylaxis. The American Academy of 
Pediatrics (AAP) revised the bronchiolitis policy statement and recommended the 
use of palivizumab in children younger than 24 months old with hemodynamically 
significant CHD in 2003. California statewide hospital discharge data from years 2000 
to 2002 (pre-AAP policy revision) were compared to those from years 2004 to 2006 
(post-AAP policy revision). Overall RSV hospitalization rate was 71 per 10,000 chil-
dren younger than 2 years. 3.0% were children with CHD and 0.50% hemodynami-
cally significant CHD. HS-CHD patients accounted for 0.56% of RSV hospitalizations 
in 2000–2002, compared to 0.46% RSV hospitalizations in 2004–2006, which means 
a 19% reduction in RSV hospitalizations among HS-CHD patients after 2003 [19].
4.2 Recommendations for the use of palivizumab in RSV prevention
As shown in many trials, RSV infections still represent increased complication 
rates in high-risk populations like infants and young children with CHD [2, 10, 11, 20]. 
There is consensus that palivizumab currently is the only licensed immunoprophy-
laxis that can and should be offered [21–33].
In this subsection the guidelines and recommendations for palivizumab use 
in children with CHD in the German-speaking countries will be compared to the 
guidelines of the USA, the UK, and Canada [21–30].
Table 1 summarizes the most important points of the latest recommendations.
There are substantial differences particularly regarding the age groups of children 
with CHD, who shall or may receive immunoprophylaxis. All national committees 
agree on the fact that only children with hemodynamically significant CHD shall get 
palivizumab. Therefore, if the CHD is considered not hemodynamically significant, 
i.e., without indication for corrective surgery, intervention or cardiac medication, for 
example, small atrial septal defects (ASDs), small ventricular septal defects (VSDs), 
patent ductus arteriosus (PDA), mild aortic or pulmonary stenosis, or mild coarcta-
tion, there is no indication for palivizumab. After corrective surgery or interven-
tion is performed, there is no need of palivizumab anymore as the risk is no longer 
elevated, unless the patients require further cardiac medication or there are other 
risk factors for severe RSV disease. In this case, the administration of palivizumab 
after cardiopulmonary bypass shall be given as soon as the patient is stable.
The definition for hemodynamically significant CHD is not consistent through-
out the national recommendations.
All of them have in common that cyanotic CHD is considered significant, as well 
as the presence of pulmonary hypertension. While the recommendations in the 
USA suggest prophylaxis for moderate and severe pulmonary hypertension (PH), in 
Switzerland palivizumab shall just be offered for children with severe PH [25, 28].
The latest American Academy of Pediatrics (AAP) recommendations suggest 
prophylaxis for children, who are born within 12 months of onset of the RSV season 
and suffer from hemodynamically significant heart disease. Consultation with a 
cardiologist for decisions about prophylaxis is recommended for patients with cya-
notic heart disease. Children with acyanotic HS-CHD, who are receiving medica-
tion to control congestive heart failure and will require cardiac surgical procedures, 
and infants with moderate to severe pulmonary hypertension, as well as children 
younger than 2 years who undergo cardiac transplantation during the RSV season 
may be considered for palivizumab prophylaxis [25].
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The dosage of palivizumab is 15 mg/kg body weight in all recommendations. 
Prophylaxis shall be provided in the RSV season, which in the northern hemisphere 
is November until March, with slight differences in some US areas. Five monthly 
doses of the antibody shall be administered to provide antibody levels for 6 months.
Another important factor is to improve compliance by parental education. A 
large study from the Canadian registry of palivizumab found out that adherence to 
the monthly injection regimen was significantly associated with a lower incidence 
of RSV infections [34].
4.3 Pharmacoeconomics
Due to the high costs of palivizumab, which exceed the costs of RSV-related hos-
pitalizations, the cost-effectiveness of the product is considered controversial [19].
A cost-utility trial performed in Spain published in 2017 estimated the cost-
effectiveness of immunoprophylaxis with palivizumab versus placebo among 
Country Age Type of cardiac disease
Austria <24 m
>24 m
HS-CHD
• Cyanotic or acyanotic
• Pulmonary hypertension
Myocarditis, dilatative cardiomyopathy, congestive heart failure
High-risk constellation
Germany <6 m
6–12 m
“Shall”
HS-CHD (requires surgery or intervention)
• Cyanotic
• Pulmonary hypertension
• Pulmonary venous congestion
Congestive heart failure, requires medication
“Can”
Switzerland <12 m HS-CHD
• Cyanotic
• Pulmonary hypertension
• No surgery before RSV season
Congestive heart failure
USA <12 m
12–24 m
HS-CHD
• Cyanotic or acyanotic
• Pulmonary hypertension
Cardiomyopathy requiring medication for congestive heart failure post-heart 
transplantation
Canada <12 m
12–24 m
HS-CHD
• Cyanotic or acyanotic
• Requiring corrective surgery
• On cardiac medication
Ongoing HS-CHD case-by-case
UK <12 m HS-CHD
Plus significant co-morbidities
Table 1. 
Recommendations of different national committees on palivizumab prophylaxis in children with CHD.
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children with CHD. It concluded not only costs of hospitalization but also the 
impact of delayed cardiac surgery and the complications of performed surgery 
despite infections. The sequelae of asthma and allergic sensitization were put into 
calculation as well as indirect costs like parental absence from work. The model 
demonstrated that palivizumab prophylaxis results in more quality-adjusted life 
years (QALY) than placebo in children with CHD. Palivizumab prophylaxis was 
shown to be a cost-effective health-care intervention according to the commonly 
accepted standards of cost-effectiveness in Spain [35].
A nationwide cost-utility study based on epidemiological data over 16 RSV 
seasons performed in Austria compared the costs per QALY years in high-risk 
populations. Overall these long-term epidemiological data suggest that palivizumab 
is cost-effective in the prevention of RSV diseases in all groups. The results showed 
lowest costs per QALY years in patients with CHD (8484€) compared to 26,212€ in 
preterms and 24,654€ in BPD patients [36].
Data on cost-effectiveness still remains controversial but considering the limited 
treatment strategies for severe RSV infections and possible severe consequences in 
this especially vulnerable patient cohort may actually justify the costs of this only 
licensed immunoprophylaxis.
5. Conclusion
LRTIs caused by RSV among children with CHD put patients under high risk of 
developing respiratory or congestive heart failure. Regarding the increased fatality 
rates of RSV infections among infants and young children with CHD, immunoprophy-
laxis with palivizumab may be justified in this patient collective. Used properly (start-
ing in time with regular repetitions throughout the RSV season) palivizumab leads to 
a significant decrease in RSV-related hospitalization rates, as well as ICU days, days on 
mechanical ventilation, and days on supplemental oxygen. Unless a vaccine against 
RSV is found, immunoprophylaxis with palivizumab remains the only way to reduce 
the burden of RSV disease among this high-risk patient collective at the moment.
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